Figure 6.
Medium supernatant of HepG2 cells, which were treated with BRL37344, increases ABCA1 but not ABCG1 expression in macrophages.
Notes: Western blot analysis of ABCA1 (A) and ABCG1 (B) performed in lipid-loaded RAW264.7 cells. Vehicle group: lipid-loaded RAW264.7 cell without any supernatants treatment; control supernatant group: lipid-loaded RAW264.7 cell cocultured with supernatants from HepG2 cells with DMSO treatment; low-dose BRL37344 supernatant group: lipid-loaded RAW264.7 cells cocultured with supernatant from HepG2 cells with 10−6 mol/LBRL37344 treatment; high-dose BRL37344 supernatant group: lipid-loaded RAW264.7 cells cocultured with supernatant from HepG2 cells with 10−5 mol/LBRL37344 treatment; BRL37344 group: lipid-loaded RAW264.7 cells treated with 10−6 mol/LBRL37344 only; and SR59230A group: lipid-loaded RAW264.7 cells treated with 10−6 mol/L SR59230A only. Statistically significant differences are indicated (compared with control group, *P<0.01).
Abbreviations: ABC, ATP-binding cassette transporter; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.